Avidity Partners 13F holdings, Q3 2023
Holdings as of September 30, 2023 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 83 US equity positions worth $2.5bn in its Q3 2023 13F filing. The largest position was BSX at 4.4% of the reported book, followed by JAZZ and BDX. Against the Q2 2023 filing, it opened 9 new positions, added to 18 and reduced 23 among the top 50 holdings.
What did Avidity Partners own in Q3 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2023 |
|---|---|---|---|---|---|---|---|
| 1 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 4.4% | $109.1m | 2,065,800 | 163% | added |
| 2 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 4.2% | $103.2m | 797,500 | 13% | added |
| 3 | BDX BECTON DICKINSON & CO | Healthcare | 3.0% | $74.1m | 286,800 | -28% | reduced |
| 4 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.0% | $73.4m | 652,100 | -2% | reduced |
| 5 | MCK MCKESSON CORP | Healthcare | 2.9% | $72.3m | 166,300 | 64% | added |
| 6 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.6% | $65.0m | 967,000 | 21% | added |
| 7 | THC TENET HEALTHCARE CORP | Healthcare | 2.6% | $63.5m | 963,800 | -3% | reduced |
| 8 | CI THE CIGNA GROUP | Healthcare | 2.4% | $59.4m | 207,700 | – | new |
| 9 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 2.3% | $57.9m | 2,144,971 | -28% | reduced |
| 10 | UNH UNITEDHEALTH GROUP INC | Healthcare | 2.3% | $56.6m | 112,200 | – | new |
| 11 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.2% | $54.5m | 450,000 | 51% | added |
| 12 | HUM HUMANA INC | Healthcare | 2.2% | $53.7m | 110,300 | – | new |
| 13 | ARVN ARVINAS INC | Healthcare | 2.1% | $51.4m | 2,614,960 | -6% | reduced |
| 14 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 2.0% | $50.3m | 715,000 | 30% | added |
| 15 | KARUNA THERAPEUTICS INC | 2.0% | $48.5m | 286,700 | -35% | reduced | |
| 16 | REGN REGENERON PHARMACEUTICALS | Healthcare | 1.9% | $47.7m | 58,000 | 134% | added |
| 17 | ZTS ZOETIS INC | Healthcare | 1.8% | $45.6m | 262,100 | 21% | added |
| 18 | IMVT IMMUNOVANT INC | Healthcare | 1.8% | $45.1m | 1,173,662 | -44% | reduced |
| 19 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 1.8% | $44.3m | 777,172 | 94% | added |
| 20 | DHR DANAHER CORPORATION | Healthcare | 1.8% | $43.8m | 176,600 | – | new |
| 21 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 1.7% | $42.1m | 2,100,000 | -10% | reduced |
| 22 | INTRA-CELLULAR THERAPIES INC | 1.7% | $41.7m | 801,100 | – | new | |
| 23 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.6% | $41.0m | 2,821,000 | -2% | reduced |
| 24 | LLY ELI LILLY & CO | Healthcare | 1.6% | $40.3m | 75,000 | -44% | reduced |
| 25 | NTRA NATERA INC | Healthcare | 1.6% | $39.8m | 899,000 | 108% | added |
| 26 | ARGX ARGENX SE | Healthcare | 1.6% | $39.6m | 80,600 | -56% | reduced |
| 27 | SGRY SURGERY PARTNERS INC | Healthcare | 1.6% | $39.1m | 1,338,000 | -14% | reduced |
| 28 | LNTH LANTHEUS HLDGS INC | Healthcare | 1.6% | $38.8m | 558,400 | 128% | added |
| 29 | PCVX VAXCYTE INC | Healthcare | 1.6% | $38.5m | 756,165 | -14% | reduced |
| 30 | 2655787D BLUEPRINT MEDICINES CORP | 1.5% | $37.7m | 751,600 | 81% | added | |
| 31 | AKERO THERAPEUTICS INC | 1.5% | $37.4m | 739,100 | -28% | reduced | |
| 32 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.5% | $36.1m | 1,142,850 | – | new |
| 33 | PRVA PRIVIA HEALTH GROUP INC | Healthcare | 1.4% | $35.5m | 1,545,100 | 43% | added |
| 34 | DXCM DEXCOM INC | Healthcare | 1.4% | $35.2m | 377,700 | – | new |
| 35 | BHVN BIOHAVEN LTD | Healthcare | 1.3% | $33.4m | 1,285,400 | -3% | reduced |
| 36 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.3% | $32.5m | 1,587,429 | 20% | added |
| 37 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.3% | $32.2m | 1,756,940 | 95% | added |
| 38 | IMMUNOGEN INC | 1.2% | $30.4m | 1,917,907 | -4% | reduced | |
| 39 | BIIB BIOGEN INC | Healthcare | 1.2% | $29.7m | 115,400 | -34% | reduced |
| 40 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 1.2% | $28.9m | 6,050,212 | 119% | added |
| 41 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.2% | $28.6m | 1,063,897 | 15% | added |
| 42 | HCA HCA HEALTHCARE INC | Healthcare | 1.1% | $28.2m | 114,800 | – | new |
| 43 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 1.0% | $25.4m | 1,800,000 | – | new |
| 44 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.0% | $25.2m | 500,000 | 1223% | added |
| 45 | UHS UNIVERSAL HLTH SVCS INC | Healthcare | 0.9% | $22.9m | 182,000 | -51% | reduced |
| 46 | CUREVAC N V | 0.9% | $21.3m | 3,116,100 | -28% | reduced | |
| 47 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.8% | $20.7m | 296,800 | -46% | reduced |
| 48 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 0.8% | $19.4m | 544,000 | -40% | reduced |
| 49 | PROTHENA CORP PLC | 0.7% | $18.4m | 382,305 | -29% | reduced | |
| 50 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.7% | $18.2m | 657,200 | -39% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.